Naoto Ueno, MD

Articles

Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.

Naoto Ueno, MD, PhD, Discusses QOL With Trastuzumab Deruxtecan in HR+, HER2-Low Metastatic Breast Cancer

September 12th 2022

Treatment with fam-trastuzumab deruxtecan-nxki yielded promising patient-reported outcomes in patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to Naoto Ueno, MD, PhD.

Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation

Richard Champlin, MD;Issa F. Khouri, MD;Paolo Anderlini, MD;Marcos J. G. De Lima, MD;Chitra Hosing, MD;John Mcmannis, PhD;Jeffrey Molldrem, MD;Naoto Ueno, MD;Sergio Giralt, MD

January 1st 2003

High-dose myeloablative therapy with allogeneic hematopoietictransplantation is an effective treatment for hematologic malignancies,but this approach is associated with a high risk of complications.The use of relatively nontoxic, nonmyeloablative, or reduced-intensitypreparative regimens still allows engraftment and the generation ofgraft-vs-malignancy effects, is potentially curative for susceptiblemalignancies, and reduces the risk of treatment-related morbidity.Two general strategies along these lines have emerged, based on theuse of (1) immunosuppressive chemotherapeutic drugs, usually apurine analog in combination with an alkylating agent, and (2) lowdosetotal body irradiation, alone or in combination with fludarabine(Fludara).